About SeylanMED

About company

SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis. SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK. SeylanMED is funded by angel investors including board-certified dermatologists.